Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 26 04:00PM ET
0.6659
Dollar change
+0.0258
Percentage change
4.03
%
Index- P/E- EPS (ttm)-0.89 Insider Own29.16% Shs Outstand83.95M Perf Week0.74%
Market Cap55.90M Forward P/E- EPS next Y-0.39 Insider Trans0.00% Shs Float59.47M Perf Month-6.21%
Income-69.07M PEG- EPS next Q-0.19 Inst Own41.51% Short Float0.75% Perf Quarter33.98%
Sales20.55M P/S2.72 EPS this Y19.95% Inst Trans-1.65% Short Ratio0.18 Perf Half Y-5.29%
Book/sh1.13 P/B0.59 EPS next Y51.10% ROA-43.78% Short Interest0.45M Perf Year-26.82%
Cash/sh1.28 P/C0.52 EPS next 5Y14.50% ROE-66.29% 52W Range0.41 - 2.05 Perf YTD-17.79%
Dividend Est.- P/FCF- EPS past 5Y- ROI-71.67% 52W High-67.52% Beta0.98
Dividend TTM- Quick Ratio3.44 Sales past 5Y22.99% Gross Margin84.54% 52W Low62.41% ATR (14)0.05
Dividend Ex-Date- Current Ratio3.44 EPS Y/Y TTM43.04% Oper. Margin-391.18% RSI (14)49.76 Volatility6.89% 6.98%
Employees156 Debt/Eq0.04 Sales Y/Y TTM99.21% Profit Margin-336.12% Recom1.00 Target Price4.70
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q31.77% Payout- Rel Volume0.38 Prev Close0.64
Sales Surprise61.42% EPS Surprise19.05% Sales Q/Q207.94% EarningsNov 09 BMO Avg Volume2.48M Price0.67
SMA201.54% SMA50-4.22% SMA200-12.59% Trades Volume934,657 Change4.03%
Date Action Analyst Rating Change Price Target Change
Dec-02-22Downgrade BofA Securities Buy → Underperform $0.50
Dec-02-22Downgrade BofA Securities Buy → Underperform
Nov-12-21Downgrade Morgan Stanley Overweight → Equal-Weight $6
Apr-08-21Initiated Morgan Stanley Overweight $19
Nov-03-20Initiated Truist Buy $21
Oct-26-20Initiated JMP Securities Mkt Outperform $19
Oct-19-20Resumed H.C. Wainwright Buy $16
Sep-27-19Initiated H.C. Wainwright Buy $15
May-13-19Initiated RBC Capital Mkts Outperform $23
May-13-19Initiated BofA/Merrill Buy $17
Feb-02-24 12:00PM
Jan-29-24 08:01AM
Jan-16-24 07:01AM
Dec-21-23 09:15AM
07:01AM
07:01AM Loading…
Nov-20-23 07:01AM
Nov-09-23 08:39AM
07:01AM
Nov-03-23 12:01PM
Nov-02-23 04:01PM
Oct-22-23 06:01AM
Oct-18-23 07:01AM
Sep-13-23 08:45AM
Sep-12-23 07:01AM
Sep-06-23 08:17PM
07:01AM Loading…
07:01AM
Aug-15-23 10:20AM
Aug-10-23 08:40AM
07:01AM
Aug-03-23 07:01AM
Jul-12-23 07:22AM
Jun-10-23 05:00AM
May-31-23 09:30PM
04:45PM
May-16-23 06:08AM
May-11-23 08:25AM
07:01AM
May-09-23 05:35PM
07:01AM
May-04-23 07:02AM
07:01AM Loading…
07:01AM
Apr-26-23 11:30AM
Apr-19-23 07:00AM
Apr-14-23 04:01PM
Mar-18-23 03:12AM
Mar-17-23 06:35AM
Mar-16-23 04:18AM
Mar-15-23 08:15AM
07:00AM
Mar-13-23 07:00AM
Mar-08-23 07:00AM
Feb-13-23 07:00AM
Feb-07-23 07:00AM
Jan-04-23 07:00AM
Dec-20-22 09:11AM
Dec-15-22 07:00AM
Nov-30-22 07:00AM
Nov-16-22 05:39AM
Nov-14-22 08:15AM
07:00AM
Nov-08-22 03:40PM
Nov-07-22 10:00AM
07:00AM
Nov-02-22 10:01AM
07:00AM
Oct-20-22 07:00AM
Sep-29-22 12:00PM
Sep-27-22 08:07AM
Sep-07-22 07:00AM
Aug-11-22 08:15AM
07:00AM
Aug-04-22 07:00AM
Jul-25-22 08:00AM
Jul-08-22 07:27AM
Jun-21-22 09:00AM
Jun-09-22 07:00AM
Jun-05-22 09:00AM
Jun-03-22 07:00AM
May-26-22 05:15PM
May-18-22 06:41AM
May-16-22 08:15AM
07:00AM
May-12-22 05:25PM
May-09-22 08:25AM
07:00AM
May-05-22 06:05PM
May-03-22 07:00AM
May-02-22 07:00AM
Apr-28-22 09:15AM
Apr-20-22 07:00AM
Apr-13-22 11:40AM
11:01AM
07:00AM
Mar-24-22 08:15AM
07:00AM
Mar-22-22 07:00AM
Mar-17-22 07:00AM
Mar-10-22 03:00PM
Mar-08-22 04:51PM
Mar-03-22 10:05AM
Mar-02-22 07:00AM
Mar-01-22 04:01PM
Feb-16-22 08:17AM
Feb-15-22 04:06PM
Feb-09-22 07:00AM
Jan-18-22 07:00AM
Jan-04-22 07:00AM
Dec-03-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 07:45AM
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kandera ReinhardChief Financial OfficerAug 21Buy0.727,0005,07543,092Aug 22 04:01 PM
Kandera ReinhardChief Financial OfficerAug 16Buy0.718,0005,71236,092Aug 17 04:05 PM
Aldag JornChief Executive OfficerJul 11Buy0.835,0004,14271,952Jul 11 06:21 PM
Aldag JornChief Executive OfficerJul 07Buy0.815,0004,05066,952Jul 11 06:21 PM
Aldag JornChief Executive OfficerJul 05Buy0.895,0004,45061,952Jul 07 05:06 PM
Aldag JornChief Executive OfficerJul 03Buy0.895,0004,45656,952Jul 05 07:37 PM
Kandera ReinhardChief Financial OfficerJun 30Buy0.8812,00010,56028,092Jul 03 04:06 PM